Gary Hammer, M.D., Ph.D.

Millie Schembechler Professor of Adrenal Cancer
Director - Endocrine Oncology Program


After completing combined M.D., Ph.D. training at Tufts University School of Medicine, Dr. Hammer completed his residency in Internal Medicine, fellowship on Endocrinology and a post-doctoral fellowship at the University of California-San Francisco. Dr. Hammer joined the faculty at University of Michigan School of Medicine in 1999 as an Assistant Professor, was promoted to Associate Professor in 2005, and became a full Professor in 2011. Dr. Hammer now serves as Director of the Endocrine Oncology Program in the Rogel Cancer Center at the University of Michigan where he holds the Millie Schembechler Professorship in Adrenal Cancer. The Program is recognized as a worldwide leader in endocrine cancers - exemplified by its recent leadership role in the 3 recent endocrine cancer platforms of the NCI TCGA (papillary thyroid cancer, adrenocortical carcinoma and pheochromocytoma). A worldwide leader in the adrenal community, Dr. Hammer is best recognized for his research in adrenal homeostasis and neoplasia and for the treatment of adrenal cancer. Most recently, Dr. Hammer cofounded Millendo Inc., a biotechnology company focusing on therapies for adrenal cancer and other related endocrine diseases of steroid excess. Dr. Hammer has been the PI or Co-Investigator on several NIH and institutional funded grants.


Research Interests

Research projects in Dr. Hammer’s laboratory are aimed at elucidating mechanisms by which growth factor signaling and transcriptional programs initiate adrenal-specific growth and differentiation with an emphasis on dysregulated growth of adrenocortical stem/progenitor cells in development and cancer.